ZRANB2 and SYF2-mediated splicing programs converging on ECT2 are involved in breast cancer cell resistance to doxorubicin

Besides analyses of specific alternative splicing (AS) variants, little is known about AS regulatory pathways and programs involved in anticancer drug resistance. Doxorubicin is widely used in breast cancer chemotherapy. Here, we identified 1723 AS events and 41 splicing factors regulated in a breas...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Iris, Chakraborty, Alina, Saulnier, Olivier, Benoit-Pilven, Clara, Vacher, Sophie, Labiod, Dalila, Lam, Eric W F, Bièche, Ivan, Delattre, Olivier, Pouzoulet, Frédéric, Auboeuf, Didier, Vagner, Stéphan, Dutertre, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
RNA and RNA-protein complexes
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049692/
https://www.ncbi.nlm.nih.gov/pubmed/31943118
http://dx.doi.org/10.1093/nar/gkz1213

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049692/
https://www.ncbi.nlm.nih.gov/pubmed/31943118
http://dx.doi.org/10.1093/nar/gkz1213

Ejemplares similares